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      Haptoglobin is a plasma protein with hemoglobin binding capacity. Haptoglobin has important 
biological functions such as binding to free hemoglobin and removes it from the circulation, thus preventing 
iron loss and kidney damage during intravascular hemolysis, superior antioxidant capacity, protection 
against free radicals. Studies on the distribution of Hp show that the gene frequencies of Hp dependent on 
geographical and genetic family. In the other, several authors have showed the correlation between HP types 
and different diseases, such as inflammation, infection, cardiovascular diseases and malignant 
tumors.Smoking, hypertention,diabetes mellitus and serum lipid concentrations are risk factors for 
developing cardiovascular diseases. In addition, Hp polymorphism has been proposed as a risk factor for 
developing atherosclerotic vasculare disease. In this study, the association between Haptoglobin genotypic 
distribution and the incidence of coronary heart disease investigated. 50 Iranian patients with coronary heart 
disease were randomly
 
selected. Genomic DNA extracted from peripheral blood leukocytes. In PCRs with 





, respectively. In the population studied, the distribution of haptoglobin 
polymorphism was 36% (n = 18) for the Hp 1-1  type, 62% (n =31) for the HP 1-2  type, and 2% (n = 1) for 
the HP 2-2  type.  The trend in this study showing a lower frequency of 3-vessel disease and less severe 
coronary artery stenosis in patients with the HP 1-1  phenotype than in patients with the HP 1-2  phenotypes 
may be indicative of a protective effect of the HP 1-1  phenotype against the development of atherosclerotic 
coronary artery disease. 
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INTRODUCTION 
     The importance of oxidative stress and reactive 
oxygen intermediates in the atherosclerotic 
lesions in humans and animals has been well-
described [1-9]. Accordingly, differences between 
persons in their level of antioxidant protection 
may influence their risk of developing restenosis. 
Hemoglobin is an important mediator of oxidative 
tissue damage that is released from red blood cells 
at sites of vascular injury. Haptoglobin (Hp) is a 
serum protein that serves as an antioxidant by 
virtue of its ability to bind to hemoglobin and 
prevent hemoglobin-mediated oxidative tissue 
damage [10,11]. The immunological and 
antioxidant capacities of haptoglobin point 
towards a possible role in the pathogenesis of 
atherosclerosis [12]. In humans, HP is 
characterized by a genetic polymorphism of the α -
chain, with three major phenotypes: HP1-1, HP2-2 
and HP2-1, which are the expression of two alleles 
(HP1 and HP2) on chromosome 16q22.1
 
[9]. 
Haptoglobin contains β- (40 kDa) and α- (α1 = 
8.9 kDa and α2 = 16KDa) chains. The β- chains 
are identical in all, with variations dependent on 
different α- chains. Hp1-1 expresses only the α1-
chain and is the smallest form (86 KDa). Hp2-1 
and Hp2-2 express α2- chains, which can form 
polymers of 86-300 KDa (Hp2-1) and up to 900 
KDa (Hp2-2) [14]. The strength of several Hp 
functional properties differs depending on the 
 
 




specific genotype. Hp1-1 has a strong capacity for 
hemoglobin binding and antioxidative function. 
Hp2-2 functions weakly in hemoglobin binding 
and antioxidative capacity. The Hp2-1 
heterozygot is a functional intermediate [15].  
    This functional allelic polymorphism in the 
haptoglobin gene, may determine susceptibility to 
a wide variety of vascular disorders associated 
with an increase in oxidative stress [15-19]. In 
this study we characterized the frequency of 
Haptoglobin phenotype in Iranian patients with 
coronary heart disease.  
 
MATERIALS AND METHODS 
     Blood samples obtained from 50 adult patients 
with coronary heart disease (male, age: 45-70). 
Specimens were collected in tubes containing 
EDTA. Data on smoking habits, medical history 
and level of physical activity collected by self-
administered questionnaires. The Hp 1- and Hp 2-
specific sequences are contained in the 
EMBL/GenBank Data Libraries under accession 
numbers AC004682 and M69197, respectively 
(19,20). According to the sequence present in 
AC004682, the Hp 1-specific DNA region has a 
length of 1711 bp; it extends, in an inverse 
orientation, from nucleotide position 188616 to 
nucleotide position 186906. In the sequence 
present in M69197, the 3435-bp Hp 2-specific 
DNA segment starts at position 2804 and ends at 
position 6238; it contains two units of similar 
sequences, consisting of 1724 and 1711 bp. The 
sequences of the 1711-bp segments present in 
AC004682 and M69197 are complementary with 
the exception of one divergence located at 
position 188141 in AC004682, which corresponds 
to position 5003 in M69197. DNA was extracted 
from peripheral bloods by sodium per chlorate 
method have set up in my laboratory. Briefly, 500 
μl  of blood sample was suspended with 1 ml of 
lysis buffer (10mM Tris-HCl pH 8, 0.1mM EDTA, 
0.15M NaCl, 0.5% Triton X-100,) and centrifuge 
for 5 min at 8000 rpm at 4 °C and removed 
supernatant.  100 μl sodium per chlorate (4M), 10 
μl  SDS (10%) and 400 μl  TE buffer were added 
to Pellete.  100 μl of 5N NaCl was added to the 
reaction, vortexed  and centrifuged at 12000 RPM 
for 10 min. supernatant was transferred to a new 
micotube and DNA was precipitated by alcohol 
and dissolved in 100 μl dH2O. Oligonucleotide 
primers A (5-
GAGGGGAGCTTGCCTTTCCATTG-3) and B 
(5-GAGATTTTTGAGCCCTGGCTGGT-3) were 
used for amplification of a 1757-bp Hp 1 allele-
specific sequence and a 3481-bp Hp 2 allele-
specific sequence. Primers were
 
synthesized by 
Applied Biosystems. In Hp 1 and Hp 2, the 
annealing sites for primer A are located 
immediately
 
upstream of the 1711-bp unit and the 1724-bp unit,
 
respectively.  
    The nucleotide at the 5' end of primer
 
A 
corresponds to position 188639 in AC004682 (Hp 
1) and position
 
2781 in M69197 (Hp 2). Primer B 
has binding sites just downstream
 
of the 1711-bp 
elements of Hp 1 and Hp 2. The nucleotide
 
at the 
5' end of primer B corresponds to position 186883 
in
 
AC004682 (Hp 1) and position 6261 in M69197 
(Hp 2). Depending
 
on the genotype represented by 
the template DNA, a Hp 1-specific
 
product of 
1757- bp and/or a Hp 2-specific product of 3481- 
bp
 
is generated in PCRs with primers A and B. 
The 50-µL reactions contained 1 U of Taq 
polymerase (SinnGen),
 
100–1000 ng of DNA, and 
200 µM each of dATP, dCTP,
 
dGTP, and dTTP 
(Invitrogen); PCR buffer was used as suggested
 
by 
the supplier (SinnGen) with no supplements 
added. After initial
 
denaturation at 94 °C for 5 
min, the two-step thermocycling
 
procedure 
consisted of denaturation at 94 °C for 1 min and
 
annealing and extension at 66 °C for 1 min (in the 
presence
 
of primers A and B), repeated for 30 
cycles, and
 
followed by a final extension at 72 °C 
for 5 min. The thermocyclers
 
used were Corbet 
PCR systems (Applied Biosystems).
 
For genotype 
assignments, the PCR products were separated in
 
0.8% agarose gels. Genotype determinations were 
done without knowledge
 






     In PCRs with primers A and B, amplification 
products of 1757 and 3481 bp were amplified 
from genomic DNA containing alleles Hp1 and 
Hp2, respectively. After electrophoresis of the 
reaction products in 0.8% agarose gels, Hp 
genotype-specific banding patterns were obtained: 
genotypes Hp 1-1 and Hp 2-2 were characterized 
by single bands representing the 1757- and 3481-
 
 




bp products, respectively, and genotype Hp 2-1 
was characterized by the presence of both the 
1757- and 3481-bp products (fig. 1).With the 
heterozygous genotype Hp2-1, the HP1-specific 
1757-bp band was considerably more intense than 
the Hp2-specific 3481-bp band (fig. 1, lane 4). 
The haptoglobin genotypes of 50 nondiabetic 
cardiovascular patients were determined with 
genomic DNA prepared from blood samples. In 
the population studied, the distribution of 
haptoglobin polymorphism was 36% (n = 18) for 
the Hp 1-1  type, 62% (n =31) for the Hp2-1 type, 
and 2% (n = 1) for the Hp2-2 type.  
    There was a statistically significant difference in 
the distribution of the 3 Hp types between 
nondiabetic cardiovascular patients 
(P<0.001).There was 49 of the 50 patients with the
 




Hp2-2, for this reason we eliminated Hp2-2 type 
from analysis. As given in Table 1, there were no 
significant
 
differences in age, lifestyle 
characteristics, body mass index and smoking 
between these two groups. The distribution of the 
Hp phenotypes tested against Hardy-Weinberg 
equilibrium according to χ2 test [27]. Among the 
two groups Hp1-1 and Hp2-1, the equality of 
distributions of continuous variables was 
statistically evaluated according to the Kruskal– 
Wallis test, while proportions were compared 
using Fisher’s exact test. In this matched case-
control study, the association between the Hp 
polymorphism and mortality from CHD, 
independently of classical coronary risk factors, 
was modeled using conditional logistic regression 
for matched sets [29].  
     Multivariately adjusted odds ratios were 
calculated together with their 95% confidence 
intervals. Statistical significance of the estimated 
regression coefficients judged according to the 
Wald χ2 statistic. The global level for statistical 
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     Haptoglobin has been demonstrated to have 
activities related to modulation of oxidative 
stress [10,11] and inflammation [21], 
phenomena that have been shown to be 
important in the restenotic process [1 – 9]. 
Haptoglobin is an antioxidant by virtue of its 
ability to bind to hemoglobin and prevent 
hemoglobin-mediated oxidative injury [10,11]. 
The different haptoglobin phenotypes appear 
to differ in their antioxidant capacity, with the 
Hp1-1 protein being the most superior 
antioxidant [21]. Moreover, the ability of the 
different haptoglobin types to enter the 
extravascular space, where they are needed to 
neutralize hemoglobin deposited at sites of 
vascular injury, are different [21,22].Hp1-1 
protein, a dimer of 86 kd is better able to sieve 
into the extravascular space than Hp2-1 protein, 
which is a liner polymer with an effective 
molecular weight of 86 to 300 kd. Haptoglobin 
has also been demonstrated to play a role as an 
immunomodulator that may be related to its 
role in hemoglobin metabolism. A specific 
receptor for the haptoglobin-hemoglobin 
complex has been identified on 
monocyte/macrophages as CD163, a member 
of the group B scavenger receptor cysteinerich 
superfamily. CD163 binds the complexes of 
hemoglobin and multimeric Hp2-1 or 2-2 stronger 
as compared to dimeric Hp1-1 [23]. Ligand binding 
to CD163 has been shown to induce a tyrosine 
kinase-dependent signal cascade, resulting in 
secretion of a number of inflammatory cytokines 
[24].  
     According to our results, because there are no 
significant differences between coronary risk factors 
and haptoglobin phenotypes, it seems that the 
mechanism by which haptoglobin phenotype is 
related to coronary heart disease, is different from 
the mechanism by which the risk factors cause 
cardiovascular disease. The trend in this study 
showing a lower frequency of 3-vessel disease and 
less severe coronary artery stenosis in patients with 
the Hp1-1 phenotype than in patients with the Hp2-
1 phenotypes may be indicative of a protective 
effect of the Hp1-1 phenotype against the 
development of atherosclerotic coronary artery 
disease [25]. Indeed, it has been demonstrated in a 
prospective longitudinal population study using the 
Strong Heart Study [26] cohort that patients with 
the Hp2-2 and 2-1 phenotypes are at significantly 
greater risk of developing coronary heart disease 
than patients with the Hp1-1 phenotype [15].  
 
Table 1: Characteristics of the study sample by Hp phenotype.  
Significance Hp2-1 (n=31) Hp1-1 (n=18)  
0.98 58.22 (10.58) 58.27 (11.8) Age (years, mean, S.D.) 
0.066 30.52 (2.97) 29.10 (2.27) BMI (kg/m
2
, mean, S.D.) 
0.1 51.6 (16) 27.8 (5) Obesity (% yes, n) 
0.62 48.4 (15) 55.6 (10) Smoking (% current, n) 
0.97 231.48 (36.95) 232.06 (58.55) Clostrol (mg/dl ,mean, S.D.) 
0.65 140.55 (34.18) 145.61 (44.11) LDL (mg/dl, mean, S.D.) 
0.55 37.74 (10.26) 35.94 (10.26) HDL (mg/dl, mean, S.D.) 
0.055 126.71 (25.88) 142.94 (31.06) Cystolic pressure (mmHg, mean, S.D.) 
0.14 80.87 (13.08) 86.56 (12.99) Diastolic pressure (mmHg, mean, S.D.) 
 
CONCLUSION 
     We performed haptoglobin genotyping by 
polymerase chain reaction (PCR) using allele-
specific primer-pairs. The haptoglobin 





62 %; Hp2-2: 4%; The results 
indicate that Hp polymorphism, in Iranian 
population, does not predispose to the occurrence of 
cardiovascular diseases. It seems that Hp1-1 and 
Hp2-1 are independent of risk factor.  
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